Yan Ning

Title(s)Clinical Research Data Specialist Lead
SchoolKeck School of Medicine of Usc
Address2020 Zonal Ave
Health Sciences Campus
Los Angeles CA 90033
Phone+1 323 409 4365
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients. Cancers (Basel). 2020 Oct 13; 12(10). Volz NB, Hanna DL, Stintzing S, Zhang W, Yang D, Cao S, Ning Y, Matsusaka S, Sunakawa Y, Berger MD, Cremolini C, Loupakis F, Falcone A, Lenz HJ. PMID: 33065994; PMCID: PMC7601940.
      View in: PubMed   Mentions: 1  
    2. A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. PLoS One. 2020; 15(9):e0239439. Miyamoto Y, Schirripa M, Suenaga M, Cao S, Zhang W, Okazaki S, Berger MD, Matsusaka S, Yang D, Ning Y, Baba H, Loupakis F, Lonardi S, Pietrantonio F, Borelli B, Cremolini C, Yamaguchi T, Lenz HJ. PMID: 32970737; PMCID: PMC7514061.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    3. Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. Cancers (Basel). 2020 Jun 30; 12(7). Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Cremolini C, Murgioni S, Lonardi S, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Barzi A, Loupakis F, Falcone A, Lenz HJ. PMID: 32629861; PMCID: PMC7408001.
      View in: PubMed   Mentions: 2  
    4. A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. Eur J Cancer. 2020 05; 131:89-97. Berger MD, Ning Y, Stintzing S, Heinemann V, Cao S, Zhang W, Yang D, Miyamoto Y, Suenaga M, Schirripa M, Hanna DL, Soni S, Puccini A, Tokunaga R, Naseem M, Battaglin F, Cremolini C, Falcone A, Loupakis F, Lenz HJ. PMID: 32305727; PMCID: PMC7513926.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    5. Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib. Cancer Sci. 2020 Feb; 111(2):441-450. Matsusaka S, Hanna DL, Ning Y, Yang D, Cao S, Berger MD, Miyamoto Y, Suenaga M, Dan S, Mashima T, Seimiya H, Zhang W, Lenz HJ. PMID: 31821662; PMCID: PMC7004533.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    6. Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. Eur J Cancer. 2019 01; 107:100-114. Suenaga M, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Soni S, Barzi A, Heinemann V, Lenz HJ. PMID: 30554073; PMCID: PMC6367121.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    7. Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients. Int J Cancer. 2019 05 15; 144(10):2567-2577. Suenaga M, Cao S, Zhang W, Yang D, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Soni S, Barzi A, Yamaguchi T, Lenz HJ. PMID: 30411783; PMCID: PMC7497849.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. Pharmacogenomics J. 2018 09; 18(5):623-632. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Cremolini C, Lonardi S, Bergamo F, Ning Y, Yamamoto N, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Barzi A, Yamaguchi T, Stintzing S, Heinemann V, Loupakis F, Falcone A, Lenz HJ. PMID: 29925895; PMCID: PMC6151284.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    9. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. Clin Colorectal Cancer. 2018 09; 17(3):e471-e488. Hanna DL, Loupakis F, Yang D, Cremolini C, Schirripa M, Li M, Matsusaka S, Berger MD, Miyamoto Y, Zhang W, Ning Y, Antoniotti C, Salvatore L, Moran M, Zeger G, Astrow SH, Falcone A, Lenz HJ. PMID: 29636300; PMCID: PMC6110978.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    10. NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. PLoS One. 2018; 13(3):e0193640. Schirripa M, Zhang W, Yang D, Cao S, Okazaki S, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Alberti G, West JD, Lonardi S, Khoukaz T, Bergamo F, Battaglin F, Antoniotti C, Falcone A, Stintzing S, Heinemann V, Lenz HJ. PMID: 29522543; PMCID: PMC5844536.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    11. Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Clin Colorectal Cancer. 2018 06; 17(2):e395-e414. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Ning Y, Cremolini C, Antoniotti C, Borelli B, Mashima T, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Barzi A, Lonardi S, Yamaguchi T, Falcone A, Loupakis F, Lenz HJ. PMID: 29606345; PMCID: PMC7493703.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    12. A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. Clin Cancer Res. 2018 02 15; 24(4):784-793. Berger MD, Stintzing S, Heinemann V, Cao S, Yang D, Sunakawa Y, Matsusaka S, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Hanna DL, Soni S, Puccini A, Zhang W, Cremolini C, Falcone A, Loupakis F, Lenz HJ. PMID: 29208668; PMCID: PMC7505162.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    13. Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. Eur J Cancer. 2017 11; 86:197-206. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Dadduzio V, Salvatore L, Borelli B, Pietrantonio F, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Barzi A, Yamaguchi T, Loupakis F, Lenz HJ. PMID: 28992563; PMCID: PMC7497848.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    14. Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Cancer. 2017 Nov 15; 123(22):4506-4514. Okazaki S, Schirripa M, Loupakis F, Cao S, Zhang W, Yang D, Ning Y, Berger MD, Miyamoto Y, Suenaga M, Iqubal S, Barzi A, Cremolini C, Falcone A, Battaglin F, Salvatore L, Borelli B, Helentjaris TG, Lenz HJ. PMID: 28708932; PMCID: PMC5673544.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    15. Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. Int J Cancer. 2017 09 15; 141(6):1222-1230. Okazaki S, Stintzing S, Sunakawa Y, Cao S, Zhang W, Yang D, Ning Y, Matsusaka S, Berger MD, Miyamoto Y, Suenaga M, Schirripa M, West JD, Gopez R, Akihito T, Ichikawa W, Heinemann V, DePaolo RW, Lenz HJ. PMID: 28569041; PMCID: PMC5528002.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    16. Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. Int J Cancer. 2017 07 15; 141(2):383-392. Schirripa M, Zhang W, Heinemann V, Cao S, Okazaki S, Yang D, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Gopez RF, West JD, Hanna D, Barzi A, Falcone A, Stintzing S, Lenz HJ. PMID: 28369940; PMCID: PMC5510747.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    17. Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. Eur J Cancer. 2017 05; 77:13-20. Berger MD, Yamauchi S, Cao S, Hanna DL, Sunakawa Y, Schirripa M, Matsusaka S, Yang D, Groshen S, Zhang W, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Lonardi S, Cremolini C, Falcone A, Heinemann V, Loupakis F, Stintzing S, Lenz HJ. PMID: 28347919; PMCID: PMC7497847.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    18. Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection. Mol Cancer Ther. 2016 11; 15(11):2814-2821. Stremitzer S, Zhang W, Yang D, Ning Y, Sunakawa Y, Matsusaka S, Parekh A, Okazaki S, Hanna D, Astrow SH, Moran M, Hernandez J, Stephens C, Scherer SJ, Stift J, Wrba F, Gruenberger T, Lenz HJ. PMID: 27535973; PMCID: PMC8547597.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    19. Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012. Oncotarget. 2016 Aug 16; 7(33):53668-53678. Berger MD, Yang D, Sunakawa Y, Zhang W, Ning Y, Matsusaka S, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Lenz AM, Bohanes P, Barzi A, Figueiredo JC, Hanna DL, Lenz HJ. PMID: 27449091; PMCID: PMC5288213.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    20. Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab. Mol Cancer Ther. 2016 07; 15(7):1740-5. Okazaki S, Loupakis F, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Stremitzer S, Matsusaka S, Berger MD, Parekh A, West JD, Miyamoto Y, Suenaga M, Schirripa M, Cremolini C, Falcone A, Heinemann V, DePaolo RW, Lenz HJ. PMID: 27196764; PMCID: PMC4936942.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    21. TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy. Mol Cancer Ther. 2016 06; 15(6):1405-11. Matsusaka S, Zhang W, Cao S, Hanna DL, Sunakawa Y, Sebio A, Ueno M, Yang D, Ning Y, Parekh A, Okazaki S, Berger MD, Ichikawa W, Mizunuma N, Lenz HJ. PMID: 26983880; PMCID: PMC4893985.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    22. Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. Clin Cancer Res. 2016 07 01; 22(13):3218-26. Matsusaka S, Hanna DL, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Okazaki S, Berger MD, Miyamato Y, Parekh A, Stintzing S, Loupakis F, Lenz HJ. PMID: 26839145; PMCID: PMC4930688.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    23. Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. Mol Cancer Ther. 2015 Oct; 14(10):2401-8. Ning Y, Hanna DL, Zhang W, Mendez A, Yang D, El-Khoueiry R, Matsusaka S, Sunakawa Y, Stremitzer S, Parekh A, Okazaki S, Berger MD, Barzi A, Lenz HJ. PMID: 26227487; PMCID: PMC4596790.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    24. Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. Mol Cancer Ther. 2015 Oct; 14(10):2374-81. Stintzing S, Zhang W, Heinemann V, Neureiter D, Kemmerling R, Kirchner T, Jung A, Folwaczny M, Yang D, Ning Y, Sebio A, Stremitzer S, Sunakawa Y, Matsusaka S, Yamauchi S, Loupakis F, Cremolini C, Falcone A, Lenz HJ. PMID: 26206335; PMCID: PMC4596768.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    25. Non-coding RNAs derived from an alternatively spliced REST transcript (REST-003) regulate breast cancer invasiveness. Sci Rep. 2015 Jun 08; 5:11207. Lee NS, Evgrafov OV, Souaiaia T, Bonyad A, Herstein J, Lee JY, Kim J, Ning Y, Sixto M, Weitz AC, Lenz HJ, Wang K, Knowles JA, Press MF, Salvaterra PM, Shung KK, Chow RH. PMID: 26053433; PMCID: PMC4459148.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    26. Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases. Cancer. 2015 Jun 01; 121(11):1898-905. Stremitzer S, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Sunakawa Y, Yamauchi S, Matsusaka S, El-Khoueiry R, Stift J, Wrba F, Gruenberger T, Lenz HJ. PMID: 25690670; PMCID: PMC4441595.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    27. Genetic variants within obesity-related genes are associated with tumor recurrence in patients with stages II/III colon cancer. Pharmacogenet Genomics. 2015 Jan; 25(1):30-7. Sebio A, Gerger A, Matsusaka S, Yang D, Zhang W, Stremitzer S, Stintzing S, Sunakawa Y, Yamauchi S, Ning Y, Fujimoto Y, Ueno M, Lenz HJ. PMID: 25379721; PMCID: PMC4260998.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    28. Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients. Pharmacogenet Genomics. 2014 Dec; 24(12):588-96. Sunakawa Y, Wakatsuki T, Yang D, Zhang W, Ning Y, Stintzing S, Stremitzer S, Yamauchi S, Sebio A, El-khoueiry R, Iqbal S, Barzi A, Gerger A, Stotz M, Azuma M, Watanabe M, Koizumi W, Lenz HJ. PMID: 25203738; PMCID: PMC4218879.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    29. Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent. Pharmacogenet Genomics. 2014 Nov; 24(11):539-47. Wakatsuki T, Stintzing S, Zhang W, Yang D, Azuma M, Ning Y, Yamauchi S, Matsusaka S, Volz NB, Sunakawa Y, Koizumi W, Watanabe M, Barzi A, El Khoueiry AB, Shah MA, Lenz HJ. PMID: 25203737; PMCID: PMC4190127.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    30. Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy. Mol Cancer Ther. 2014 Feb; 13(2):528-39. Ning Y, Gerger A, Zhang W, Hanna DL, Yang D, Winder T, Wakatsuki T, Labonte MJ, Stintzing S, Volz N, Sunakawa Y, Stremitzer S, El-Khoueiry R, Lenz HJ. PMID: 24170770; PMCID: PMC3945969.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    31. Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States. Mol Cancer Ther. 2013 Oct; 12(10):2261-72. Wakatsuki T, LaBonte MJ, Bohanes PO, Zhang W, Yang D, Azuma M, Barzi A, Ning Y, Loupakis F, Saadat S, Volz N, Stintzing S, El-Khoueiry R, Koizumi W, Watanabe M, Shah M, Stebbing J, Giamas G, Lenz HJ. PMID: 23918832; PMCID: PMC3810398.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    32. Influence of sex on the survival of patients with esophageal cancer. J Clin Oncol. 2012 Jun 20; 30(18):2265-72. Bohanes P, Yang D, Chhibar RS, Labonte MJ, Winder T, Ning Y, Gerger A, Benhaim L, Paez D, Wakatsuki T, Loupakis F, El-Khoueiry R, Zhang W, Lenz HJ. PMID: 22585694; PMCID: PMC3397720.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    33. Targeting IL-8 in colorectal cancer. Expert Opin Ther Targets. 2012 May; 16(5):491-7. Ning Y, Lenz HJ. PMID: 22494524.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    34. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. Mol Cancer Ther. 2012 Jun; 11(6):1353-64. Ning Y, Labonte MJ, Zhang W, Bohanes PO, Gerger A, Yang D, Benhaim L, Paez D, Rosenberg DO, Nagulapalli Venkata KC, Louie SG, Petasis NA, Ladner RD, Lenz HJ. PMID: 22391039.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansAnimalsCells
    35. Cancer dormancy: a model of early dissemination and late cancer recurrence. Clin Cancer Res. 2012 Feb 01; 18(3):645-53. Páez D, Labonte MJ, Bohanes P, Zhang W, Benhanim L, Ning Y, Wakatsuki T, Loupakis F, Lenz HJ. PMID: 22156560.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansCells
    36. Common cancer stem cell gene variants predict colon cancer recurrence. Clin Cancer Res. 2011 Nov 01; 17(21):6934-43. Gerger A, Zhang W, Yang D, Bohanes P, Ning Y, Winder T, LaBonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, El-Khoueiry A, Kahn M, Lenz HJ. PMID: 21918173.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCells
    37. Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. J Gastrointest Oncol. 2011 Jun; 2(2):77-84. Yang D, Hendifar A, Lenz C, Togawa K, Lenz F, Lurje G, Pohl A, Winder T, Ning Y, Groshen S, Lenz HJ. PMID: 22811834; PMCID: PMC3397601.
      View in: PubMed   Mentions: 84  
    38. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer. 2011 May 01; 128(9):2038-49. Ning Y, Manegold PC, Hong YK, Zhang W, Pohl A, Lurje G, Winder T, Yang D, LaBonte MJ, Wilson PM, Ladner RD, Lenz HJ. PMID: 20648559; PMCID: PMC3039715.
      View in: PubMed   Mentions: 179     Fields:    Translation:HumansAnimalsCells
    39. Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma. Int J Cancer. 2011 Sep 01; 129(5):1096-104. Winder T, Ning Y, Yang D, Zhang W, Power DG, Bohanes P, Gerger A, Wilson PM, Lurje G, Tang LH, Shah M, Lenz HJ. PMID: 21105049; PMCID: PMC3139396.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    40. Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients. Clin Cancer Res. 2010 Nov 15; 16(22):5591-602. Winder T, Zhang W, Yang D, Ning Y, Bohanes P, Gerger A, Wilson PM, Pohl A, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ. PMID: 20935157; PMCID: PMC2982939.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    41. Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). Anticancer Res. 2010 Oct; 30(10):4209-17. Zhang W, Azuma M, Lurje G, Gordon MA, Yang D, Pohl A, Ning Y, Bohanes P, Gerger A, Winder T, Hollywood E, Danenberg KD, Saltz L, Lenz HJ. PMID: 21036743.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    42. Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus. Ann Surg. 2010 May; 251(5):857-64. Lurje G, Leers JM, Pohl A, Oezcelik A, Zhang W, Ayazi S, Winder T, Ning Y, Yang D, Klipfel NE, Chandrasoma P, Hagen JA, DeMeester SR, DeMeester TR, Lenz HJ. PMID: 20101173.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    43. Gender disparities in metastatic colorectal cancer survival. Clin Cancer Res. 2009 Oct 15; 15(20):6391-7. Hendifar A, Yang D, Lenz F, Lurje G, Pohl A, Lenz C, Ning Y, Zhang W, Lenz HJ. PMID: 19789331; PMCID: PMC2779768.
      View in: PubMed   Mentions: 82     Fields:    Translation:Humans
    44. Thymidylate synthase gene variations: predictive and prognostic markers. Mol Cancer Ther. 2009 May; 8(5):1000-7. Lurje G, Manegold PC, Ning Y, Pohl A, Zhang W, Lenz HJ. PMID: 19383851.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    45. Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer. Pharmacogenet Genomics. 2009 Feb; 19(2):95-102. Lurje G, Hendifar AE, Schultheis AM, Pohl A, Husain H, Yang D, Manegold PC, Ning Y, Zhang W, Lenz HJ. PMID: 18987561.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    46. Targeting metastatic colorectal cancer in 2008: a long way from 5-FU. Oncology (Williston Park). 2008 Apr 15; 22(4):456-62; discussion 462-3, 467-8, 474 passim. Pohl A, Zhang W, Ning Y, Manegold PC, Lurje G, Lenz HJ. PMID: 18472617.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    47. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics. 2008 Feb; 18(2):161-8. Lurje G, Zhang W, Yang D, Groshen S, Hendifar AE, Husain H, Nagashima F, Chang HM, Fazzone W, Ladner RD, Pohl A, Ning Y, Iqbal S, El-Khoueiry A, Lenz HJ. PMID: 18192902.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    Yan's Networks
    Concepts (218)
    Derived automatically from this person's publications.
    _
    Co-Authors (13)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _